Riskpilot← Back to searchSign inGet full accessGalecto Biotech AB
ABActiveOrg 5568728413Research and experimental development on natural sciences and engineering · NACE 7210Est. 20111 employees
Revenue 2024
SEK 0
EBITDA margin
—
+64% vs 2023
Equity ratio
12.6%
Financial strength
Net profit 2024
SEK -110,8M
+65% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -120,7M | +64% |
| Net profit | SEK -110,8M | +65% |
| Total assets | SEK 108,1M | +19% |
| Equity | SEK 13,6M | -31% |
| Employees | 1 | — |
Legal name
Galecto Biotech AB
Org number
5568728413
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22 november 2011
Share capital
SEK 2 779 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas i förening av Burkavage, Brian Albert Winslow, Garrett Michael
Company purpose
Bolaget ska identifiera, utveckla och marknadsföra galektininhibitorer som läkemedel för behandling av fibros, cancer, inflammation och andra sjukdomar, samt annan verksamhet som är förenlig därmed. Bolaget ska även kunna bedriva kapitalförvaltning.
Address
Email
hs@galecto.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 13 034 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −838 | −367 | −2 612 | −136 081 | −20 751 | −240 643 | −36 014 | −549 072 | −338 524 | −120 720 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −838 | −367 | −2 612 | −136 081 | −20 751 | −240 643 | −36 014 | −549 072 | −338 524 | −120 720 |
| Net financials | 217 | 243 | −24 | −6 737 | −130 | 25 688 | 212 | −9 954 | −671 | −6 269 |
| Profit before tax | −622 | −123 | −2 636 | −142 829 | −20 881 | −214 954 | −35 802 | −559 015 | −339 195 | −126 989 |
| Tax | 125 | 27 | 336 | 7 558 | 830 | 8 007 | 884 | 8 464 | 20 168 | 16 213 |
| Net profit | −497 | −96 | −2 300 | −135 271 | −20 051 | −206 947 | −34 918 | −550 551 | −319 027 | −110 776 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 9 721 | 9 201 | 12 395 | 294 456 | 10 833 | 168 586 | 14 295 | 197 901 | 90 899 | 108 062 |
| Equity | 9 597 | 9 068 | 6 565 | 276 521 | 5 405 | 152 361 | 11 895 | 27 482 | 19 672 | 13 593 |
| Long-term debt | 0 | 0 | 5 433 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 124 | 133 | 397 | 17 936 | 5 427 | 16 235 | 2 400 | 170 419 | 71 227 | 94 469 |
| Total debt | 124 | 133 | 5 830 | 17 936 | 5 427 | 16 235 | 2 400 | 170 419 | 71 227 | 94 469 |
EBITDA margin
-12072000000.0%
This company
15.8%
Market median
-76405063391% vs market
20152024
Equity ratio
12.6%
This company
38.2%
Market median
-67% vs market
20152024
Return on equity
-814.9%
This company
18.4%
Market median
-4529% vs market
20152024
Net profit margin
-11077600000.0%
This company
8.1%
Market median
-136760493927% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
6.95×
This company
0.62×
Market median
-1021% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JC Chief Auditor | Chief Auditor | 2025 | — | — |
NE Chief Auditor | Chief Auditor | 2020 | — | — |
LO Authorized Recipient of Service | Authorized Recipient of Service | 2022 | — | — |
LJ External Signatory | External Signatory | 2020 | — | — |
NA Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2025 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
GALECTO INC. | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
GALECTO INC.
Galecto Biotech AB (this company)Galecto Biotech ApsGALECTO BIOTECH APSBoard members of Galecto Biotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Christian Andersson | Chief Auditor | 0 companies |
| Nina Elisabeth Bergman | Chief Auditor | 0 companies |
| Lars Ola Grahn | Authorized Recipient of Service | 0 companies |
| Lars Jakob Dynnes Hansen | External Signatory | 0 companies |
| Nils Andreas Nyberg Selvring | Chief Auditor | 0 companies |
| Bertil Erik Lindmark | Board of Directors | 0 companies |
| Karen Ina Barbara Wagner | Board of Directors | 0 companies |
| Sören Lemonius | Board of Directors | 0 companies |
| Garrett Michael Winslow | Deputy Board Member | 0 companies |
| Jonathan Paul Freve | Deputy Board Member | 0 companies |
| Chau Quang Khuong | Board of Directors | 0 companies |
| Erez Chimovits | Board of Directors | 0 companies |
| Gunnar Magnus Severus Persson | Chairman | 0 companies |
| Søren Møller | Board of Directors | 0 companies |
| Hans Thalsgård Schambye | Chairman | 0 companies |
| Brian Albert Burkavage | Board of Directors | 0 companies |
| Chandra Paul Leo | Board of Directors | 0 companies |
| Anders Hjelbolt Pedersen | Board of Directors | 0 companies |